Agios Pharmaceuticals Résultats passés
Passé contrôle des critères 0/6
Agios Pharmaceuticals a connu une croissance annuelle moyenne de ses bénéfices de 25.9%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 36.2% par an. Les revenus ont augmenté de en hausse à un taux moyen de 51.4% par an.
Informations clés
25.91%
Taux de croissance des bénéfices
24.71%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | 51.39% |
| Rendement des fonds propres | -38.10% |
| Marge nette | -639.84% |
| Prochaine mise à jour des résultats | 30 Jul 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Jul 07
AGIO: Sickle Cell Priority Review Momentum Will Limit Future Share Upside
Agios Pharmaceuticals' fair value estimate has moved from $28.00 to $31.00 as analysts factor in the recent series of higher price targets tied to FDA Priority Review for mitapivat in sickle cell disease, along with expectations for an accelerated launch timeline supported by an expanding hematologist prescriber base. Analyst Commentary Recent Street research on Agios Pharmaceuticals highlights a mix of optimism around mitapivat in sickle cell disease and a more cautious stance on execution risk, label breadth, and broader biotech sector conditions.Article d’analyse • Jun 17
Agios Pharmaceuticals (AGIO) Stock Could Be 22% Undervalued After RISE UP Phase 3 Data
Agios Pharmaceuticals (AGIO) stock is back in focus after the company shared detailed 52 week data from its RISE UP Phase 3 trial of mitapivat in sickle cell disease at EHA 2026. See our latest analysis for Agios Pharmaceuticals. Agios Pharmaceuticals shares have recently picked up momentum, with a 7 day share price return of 10.25% and a 30 day share price return of 12.87%. However, the 1 year total shareholder return is still down 10.31%, showing short term enthusiasm against a mixed longer...Mise à jour du récit • Jun 16
AGIO: Sickle Cell FDA Path And Thalassemia Launch Will Restrain Stock Enthusiasm
Analysts have trimmed their average price targets on Agios Pharmaceuticals stock, with recent moves such as JPMorgan's cut to $31 from $36 and BofA's adjustment to $40 from $41. These changes reflect a focus on mitapivat's thalassemia launch, the sickle cell disease regulatory path, and the pipeline changes following tebapivat's discontinued development in lower risk myelodysplastic syndromes.
Mise à jour du récit • Jun 02
AGIO: Sickle Cell FDA Path And Thalassemia Launch Will Drive Next Phase Upside
Agios Pharmaceuticals' updated analyst price target has shifted slightly lower to $40.88 from $41.13, as analysts factor in the tebapivat setback and refocus their models on mitapivat launch execution and the sickle cell disease regulatory path. Analyst Commentary Recent Street research on Agios Pharmaceuticals highlights a split view, with some analysts focusing on potential value from mitapivat and regulatory milestones, while others concentrate on pipeline setbacks, competitive pressures and addressable market questions.Seeking Alpha • May 29
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
Summary Agios Pharmaceuticals, Inc. is initiated at Sell due to pipeline setbacks and intensifying competition in PK activators. AGIO discontinued tebapivat in LR-MDS after failing a phase 2b threshold, leaving SCD as its primary near-term catalyst. Novo Nordisk's etavopivat has achieved positive phase 3 SCD results and is expected to file for approval in the 2nd half of 2026. Despite $1B in cash, company faces uncertain differentiation and commercial prospects for tebapivat in SCD, with current sales momentum limited in PYRUKYND and AQVESME. Read the full article on Seeking AlphaMise à jour du récit • May 18
AGIO: FDA Sickle Cell Decision And Trial Data Will Shape Next Phase Upside
Analysts have trimmed their consolidated price target for Agios Pharmaceuticals by about $0.40 to roughly $41.10. This reflects updated assumptions on market size, profit margins and future P/E after a mix of recent target cuts and raises across the Street.Mise à jour du récit • May 01
AGIO: Sickle Cell FDA Path And Novo Readthroughs Will Shape Future Enthusiasm
Analysts have adjusted their outlook on Agios Pharmaceuticals with a modestly lower average price target, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E following recent mixed research, including several target cuts tied to Novo Nordisk related market views and earlier target hikes linked to potential regulatory catalysts for mitapivat. Analyst Commentary Recent Street research on Agios Pharmaceuticals shows a mix of optimism around potential regulatory catalysts for mitapivat and caution around market sizing and competitive readthroughs, particularly following data points tied to Novo Nordisk.Mise à jour du récit • Apr 16
AGIO: Sickle Cell Regulatory Uncertainty Will Continue To Restrain Enthusiasm
Analysts have raised their price target on Agios Pharmaceuticals by $3 to a new fair value estimate of $28, citing recent target increases from major firms and growing attention on upcoming regulatory and clinical catalysts. Analyst Commentary Recent Street research on Agios Pharmaceuticals reflects a mix of optimism around upcoming regulatory events and ongoing caution around execution risks, valuation and timing of potential catalysts.Mise à jour du récit • Apr 02
AGIO: Upcoming Regulatory Decisions In Sickle Cell Disease Will Drive Next Phase Upside
Analysts have adjusted the fair value estimate for Agios Pharmaceuticals to $41.50 from $39.88, citing updated price targets and expectations tied to upcoming regulatory clarity on mitapivat, as well as broader support from recent research commentary. Analyst Commentary Recent Street research on Agios Pharmaceuticals centers on price target revisions, expectations around regulatory clarity for mitapivat in sickle cell disease, and the implications of the recent approval of Aqvesme.Mise à jour du récit • Mar 18
AGIO: Regulatory Clarity On Mitapivat In Sickle Cell Disease Will Drive Next Phase Upside
Analysts have lifted the fair value estimate for Agios Pharmaceuticals by $1 to $39.88, citing higher price targets, expectations for regulatory clarity around mitapivat in sickle cell disease, and the recent approval of Aqvesme as key drivers of their updated outlook. Analyst Commentary Recent Street research reflects a mix of optimism and caution around Agios Pharmaceuticals, with several price target revisions clustering in the US$25 to US$46 range and commentary centered on regulatory milestones, the impact of Aqvesme, and broader biotech sector conditions.Mise à jour du récit • Mar 04
AGIO: Thalassemia Decision And Recent Approval Will Drive Next Phase Upside
Analysts have nudged their intrinsic value estimate for Agios Pharmaceuticals higher to about $38.88 from $36.75, reflecting refreshed price targets in the $25 to $35 range and updated models following recent product approval and broader biotech sector tailwinds cited in recent research. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into the mid US$20s to mid US$30s, which aligns with the higher intrinsic value estimate around US$38.88 and indicates they see room for the shares to better reflect updated assumptions.Mise à jour du récit • Feb 18
AGIO: Sickle Cell Setback Will Continue To Restrain Enthusiasm Despite Thalassemia Approval
Analysts have lifted their fair value estimate for Agios Pharmaceuticals shares from $20 to $25, citing updated models that reflect recent drug approvals, ongoing FDA review milestones, and a series of higher Street price targets across the biotech sector. Analyst Commentary Recent Street research on Agios Pharmaceuticals reflects a split view, with several bullish initiations and target hikes alongside more cautious revisions that highlight execution and growth risks around the company’s pipeline and commercial plans.Mise à jour du récit • Feb 03
AGIO: Thalassemia Decision And Aqvesme Approval Will Define Post RISE UP Upside
Narrative Update: Agios Pharmaceuticals (AGIO) Analysts have lifted Agios Pharmaceuticals' price targets into a US$25 to US$38 range, with recent tweaks to models reflecting the approval of Aqvesme, updated views on mitapivat and Pyrukynd, and a generally more constructive stance on U.S. biotech capital and deal activity. Analyst Commentary Recent Street research on Agios Pharmaceuticals shows a wide spread of views, with price targets clustered in the US$25 to US$38 range after earlier cuts from much higher levels.Mise à jour du récit • Jan 20
AGIO: Upcoming Thalassemia Decision Will Shape Post RISE UP Opportunity Narrative
Agios Pharmaceuticals’ fair value estimate edges up from US$36.00 to US$36.75 as analysts recalibrate models following recent target changes across the Street, reflecting updated views on Pyrukynd’s opportunity set, revised profit margin assumptions, and a higher future P/E multiple, despite some ongoing trial related uncertainties. Analyst Commentary Street research around Agios has become more divided, with some analysts leaning into the updated opportunity around Pyrukynd and other mitapivat indications, while others focus on execution risk and regulatory uncertainty following the RISE UP sickle cell disease data.Mise à jour du récit • Jan 06
AGIO: Upcoming FDA Thalassemia Decision Will Shape Post RISE UP Bullish Outlook
Analysts have lifted their aggregate fair value estimate for Agios Pharmaceuticals to $36.00 from $32.13, citing updated revenue and margin assumptions. This follows mixed views on the recent RISE UP data and new Street targets that range widely from US$20 to US$48, alongside Citi's fresh US$38 initiation and a near-term FDA catalyst watch.Mise à jour du récit • Dec 18
AGIO: Sickle Cell Setback Will Drive Cautious View Despite Upcoming FDA Decision
Analysts have cut their average price target on Agios Pharmaceuticals to $20 from $37, reflecting reduced expectations for mitapivat in sickle cell disease and more conservative long term revenue and expense assumptions, even as some still see upside around upcoming regulatory catalysts for Pyrukynd. Analyst Commentary Bearish analysts have responded to the RISE UP data by sharply recalibrating expectations for mitapivat in sickle cell disease, cutting price targets and, in some cases, ratings.Mise à jour du récit • Dec 04
AGIO: Upcoming FDA Decision Will Drive Bullish Outlook After Mixed Trial Data
Analysts have reduced their average price target on Agios Pharmaceuticals from about $42 to roughly $32 per share. This reflects higher perceived risk after mixed Phase 3 RISE UP data, tempered revenue and margin expectations, and a wider debate over the regulatory and commercial outlook for mitapivat and Pyrukynd across indications.Mise à jour du récit • Nov 20
AGIO: Regulatory Decisions Will Drive Outlook After Mixed Late-Stage Clinical Results
Agios Pharmaceuticals’ analyst price target has been reduced from approximately $47.50 to $42.33 per share. Analysts cite increased uncertainty for mitapivat in sickle cell disease following underwhelming Phase 3 trial results, as well as a more challenging regulatory and commercial pathway.Mise à jour du récit • Sep 05
FDA Approval And Global Partnerships Will Yield Mixed Prospects
Analysts modestly trimmed Agios Pharmaceuticals’ price target from $47.67 to $47.50, reflecting a brief FDA approval delay for Pyrukynd and cautious near-term modeling, while maintaining long-term conviction on the strength of clinical data and emerging commercial partnerships. Analyst Commentary Bullish analysts remain confident in FDA approval of Pyrukynd despite a three-month PDUFA delay due to the submission of a REMS for hepatocellular injury, which is viewed as a standard regulatory step and not due to new data requests.Article d’analyse • Feb 20
Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem
We didn't see Agios Pharmaceuticals, Inc.'s ( NASDAQ:AGIO ) stock surge when it reported robust earnings recently. We...Seeking Alpha • Feb 14
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Summary Agios Pharmaceuticals' focus is on expanding Pyrukund's label to treat thalassemia and sickle cell disease, targeting multi-billion dollar markets. Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios' stock and could affect Pyrukund's approval and market adoption. Agios has a strong cash position of $1.5bn and potential blockbuster revenue opportunity, but safety issues warrant a cautious "Hold" rating. Monitoring progress and awaiting further clarity on safety issues and FDA decisions is advisable before making investment moves. Read the full article on Seeking Alpha
Nouveau récit • Feb 09
Mitapivat May Launch In 2025 For Blood Disorders But Faces Regulatory And Competition Challenges
Mitapivat's launch in thalassemia and sickle cell markets promises revenue growth from new opportunities, leveraging positive Phase III data for adoption.Seeking Alpha • Jan 14
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision
Summary Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their primary endpoints last year. The FDA has set a goal date of Sept. 7th 2025 to review the application and render a decision. Agios is well capitalized after $1.1 billion in milestones following the FDA's approval of vorasidenib, a drug divested when the company exited oncology in 2021. A third Phase III study named RISE UP has recruited patients to study PYRUKYND in sickle cell disease with results due in late-2025. Agios Pharma is rated a HOLD until further clarity on the commercialization of PYRUKYND occurs later this year. Read the full article on Seeking AlphaSeeking Alpha • Dec 03
Agios Pharmaceuticals: A Long Overdue Follow Up
Summary Today, we take a deeper look at commercial stage biopharma firm Agios Pharmaceuticals for the first time in more than two years. The shares have spiked up recently thanks in a large part to a huge cash infusion the company received in August. The company's one approved product on the market, PYRUKYND, has seen limited sales to date, but the compound is being evaluated to treat much larger potential indications. Read the full article on Seeking AlphaArticle d’analyse • Sep 26
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 27
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Summary Agios’ Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 trials showing positive results for hemoglobin improvement. Expanding Pyrukynd’s label to include pediatric and thalassemia indications is crucial, with regulatory filings expected by 2025. Agios has a strong financial position, with a cash runway extending beyond 2027, bolstered by milestone payments. Despite risks, Agios’ mitapivat could become a blockbuster drug, making AGIO a compelling buy for biotech investors. Read the full article on Seeking AlphaArticle d’analyse • Aug 04
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) just released its latest second-quarter report and things are not looking...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Agios Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 66 | -423 | 187 | 0 |
| 31 Dec 25 | 54 | -413 | 180 | 0 |
| 30 Sep 25 | 45 | -401 | 180 | 0 |
| 30 Jun 25 | 41 | 650 | 178 | 0 |
| 31 Mar 25 | 37 | 666 | 167 | 0 |
| 31 Dec 24 | 36 | 674 | 157 | 0 |
| 30 Sep 24 | 33 | 674 | 140 | 0 |
| 30 Jun 24 | 31 | -365 | 128 | 0 |
| 31 Mar 24 | 29 | -353 | 123 | 0 |
| 31 Dec 23 | 27 | -352 | 120 | 0 |
| 30 Sep 23 | 24 | -220 | 117 | 0 |
| 30 Jun 23 | 20 | -210 | 121 | 0 |
| 31 Mar 23 | 19 | -218 | 119 | 0 |
| 31 Dec 22 | 14 | -232 | 122 | 0 |
| 30 Sep 22 | 10 | -367 | 120 | 0 |
| 30 Jun 22 | 6 | -369 | 118 | 0 |
| 31 Mar 22 | 1 | -360 | 119 | 0 |
| 31 Dec 21 | 0 | -357 | 121 | 0 |
| 30 Sep 21 | 0 | -342 | 116 | 221 |
| 30 Jun 21 | 0 | -337 | 117 | 221 |
| 31 Mar 21 | 0 | -336 | 117 | 221 |
| 31 Dec 20 | 0 | -329 | 115 | 0 |
| 30 Sep 20 | 35 | -347 | 124 | 0 |
| 30 Jun 20 | 61 | -374 | 129 | 0 |
| 31 Mar 20 | 88 | -402 | 132 | 0 |
| 31 Dec 19 | 0 | -301 | 102 | 214 |
| 30 Sep 19 | 112 | -401 | 129 | 0 |
| 30 Jun 19 | 102 | -389 | 127 | 0 |
| 31 Mar 19 | 116 | -348 | 121 | 0 |
| 31 Dec 18 | 94 | -346 | 114 | 0 |
| 30 Sep 18 | 74 | -343 | 105 | 0 |
| 30 Jun 18 | 70 | -325 | 91 | 0 |
| 31 Mar 18 | 41 | -339 | 81 | 0 |
| 31 Dec 17 | 43 | -315 | 71 | 0 |
| 30 Sep 17 | 56 | -283 | 64 | 0 |
| 30 Jun 17 | 53 | -269 | 58 | 0 |
| 31 Mar 17 | 49 | -241 | 55 | 0 |
| 31 Dec 16 | 70 | -198 | 51 | 0 |
| 30 Sep 16 | 53 | -183 | 46 | 0 |
| 30 Jun 16 | 50 | -160 | 44 | 0 |
| 31 Mar 16 | 56 | -136 | 40 | 0 |
| 31 Dec 15 | 59 | -118 | 36 | 0 |
| 30 Sep 15 | 68 | -104 | 32 | 0 |
Des revenus de qualité: AGIO n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: AGIO n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: AGIO n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 25.9% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de AGIO au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: AGIO n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 54.5% ).
Rendement des fonds propres
ROE élevé: AGIO a un retour sur capitaux propres négatif ( -38.1% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/10 01:22 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Agios Pharmaceuticals, Inc. est couverte par 28 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Peter Lawson | Barclays |
| George Farmer | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |